Arovella Therapeutics Ltd (ALA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.71 Million ≈ $-1.21 Million USD) by net assets (AU$18.92 Million ≈ $13.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arovella Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Arovella Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Arovella Therapeutics Ltd for a breakdown of total debt and financial obligations.
Arovella Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arovella Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PW Consolidated Bhd
KLSE:7134
|
0.093x |
|
Edelteq Holdings Berhad
KLSE:0278
|
0.007x |
|
Chang Type Industrial Co Ltd
TW:1541
|
0.021x |
|
EstechPharma Co. Ltd
KQ:041910
|
0.018x |
|
ADVENICA AB
F:65R
|
0.098x |
|
Hyundai HT CoLtd
KQ:039010
|
0.046x |
|
Articore Group Ltd
AU:ATG
|
-1.004x |
|
An-Shin Food Services Co Ltd
TWO:1259
|
0.060x |
Annual Cash Flow Conversion Efficiency for Arovella Therapeutics Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Arovella Therapeutics Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ALA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$20.08 Million ≈ $14.21 Million |
AU$-6.93 Million ≈ $-4.90 Million |
-0.345x | +43.94% |
| 2024-06-30 | AU$11.23 Million ≈ $7.94 Million |
AU$-6.91 Million ≈ $-4.89 Million |
-0.616x | +63.62% |
| 2023-06-30 | AU$3.78 Million ≈ $2.67 Million |
AU$-6.40 Million ≈ $-4.53 Million |
-1.692x | -105.66% |
| 2022-06-30 | AU$7.62 Million ≈ $5.39 Million |
AU$-6.27 Million ≈ $-4.44 Million |
-0.823x | -108.53% |
| 2021-06-30 | AU$8.98 Million ≈ $6.36 Million |
AU$-3.54 Million ≈ $-2.51 Million |
-0.395x | +43.41% |
| 2020-06-30 | AU$4.14 Million ≈ $2.93 Million |
AU$-2.88 Million ≈ $-2.04 Million |
-0.697x | -290.58% |
| 2019-06-30 | AU$13.98 Million ≈ $9.89 Million |
AU$-2.50 Million ≈ $-1.77 Million |
-0.179x | +19.67% |
| 2018-06-30 | AU$11.46 Million ≈ $8.11 Million |
AU$-2.55 Million ≈ $-1.80 Million |
-0.222x | -338.46% |
| 2017-06-30 | AU$16.85 Million ≈ $11.92 Million |
AU$-854.22K ≈ $-604.42K |
-0.051x | +53.29% |
| 2016-06-30 | AU$16.61 Million ≈ $11.75 Million |
AU$-1.80 Million ≈ $-1.28 Million |
-0.109x | +33.60% |
| 2015-06-30 | AU$19.30 Million ≈ $13.66 Million |
AU$-3.15 Million ≈ $-2.23 Million |
-0.163x | +0.04% |
| 2014-06-30 | AU$15.99 Million ≈ $11.32 Million |
AU$-2.61 Million ≈ $-1.85 Million |
-0.164x | +32.03% |
| 2013-06-30 | AU$6.69 Million ≈ $4.73 Million |
AU$-1.61 Million ≈ $-1.14 Million |
-0.241x | -- |
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more